CYB
Aucyber Limited
🇦🇺 ASX
🤖 TECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-20.53%
Annual Growth
4 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
1
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
AUCyber Ltd. provides cloud based infrastructure as a service. The company is headquartered in Canberra, Australian Capital Territory. The company went IPO on 2020-12-14. The firm specializes in delivering highly secure cloud infrastructure alongside managed cybersecurity and consulting services for prominent enterprise and government customers. The firm encompasses brands: AUCyber and AUCloud, Australian sovereign providers of comprehensive cybersecurity, secure private cloud and managed technology services. With national operations, the Company leverages the sovereign cloud infrastructure and employs Australian security-cleared engineers, security analysts, IT professionals, and holds the highest security accreditations. Its solutions are backed by key certifications, including the Digital Transformation Agency’s Hosting Certification Framework and compliance with the Australian Signals Directorate’s Information Security Manual. These certifications provide customers with confidence in the security and quality of its services.
📈 Performance
Price History
-88.67%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.09
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CYB
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in CYB
4 days
CYB investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in CYB also invest in...
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
10.90%
📊 Share price
$14.80 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
💸 FINANCIALS
📈 HIGH PRICE GROWTH
⛳️ DIVERSIFIED
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
🙌 Performance (5Yr p.a)
13.53%
📊 Share price
$77.13 AUD
🌏 GLOBAL
🏭 INDUSTRIALS
🛍️ CONSUMER
📈 HIGH PRICE GROWTH
Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. The firm is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. The company is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.
🙌 Performance (5Yr p.a)
61.43%
📊 Share price
$1.14 AUD
🧬 BIOTECHNOLOGY
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
8.32%
📊 Share price
$94.88 AUD
💸 FINANCIALS
🧱 MATERIALS
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
FANG.AX was created on 2020-02-27 by ETFS. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the NYSE FANG.AX+ Index (the Index).
🙌 Performance (5Yr p.a)
34.22%
📊 Share price
$26.92 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
📞 COMMUNICATIONS
Want more shares? Try these...
